rf-fullcolor.png

 

June 26, 2012
by RAPS

FDASIA Legislation Moves to Vote in Senate

The Food and Drug Administration Safety and Innovation Act (FDASIA), a massive piece of legislation aimed at renewing industry funding provisions for the US Food and Drug Administration (FDA) and making a number of regulatory changes at the agency, is on pace for approval on Tuesday, 26 June 2010.

In a vote to end debate-known as a Cloture Motion-on Monday, 89 Senators voted in favor of the motion while just three Senators-Richard Burr (R-NC), Bernie Sanders (I-VT) and Rand Paul (R-KY)-voted against the motion. Eight Senators were not present for the motion and did not vote.

The Hill's Floor Action Blog reports the measure is still subject to "several hours of post-cloture debate on the bill," but based on the Senate's earlier near-unanimous approval of the bill, passage seems all but assured.

After approval in the Senate, the bill, which has already been approved in the House of Representatives, would go to President Barack Obama for his signature. The current pace of legislation indicates the legislation would likely be signed into law by Obama in early July 2012, with the law coming into effect in October 2012 when the previous user fee acts expire.


Read more:

Senate: U.S. Senate Roll Call Votes 112th Congress - 2nd Session

The Hill - Tuesday: FDA in the Senate, maritime security in the House

The Pink Sheet - FDASIA Primed For Final Senate Vote After Cloture Motion Passes

Modern Healthcare - FDA user-fee legislation moves toward final vote

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.